China's active pharmaceutical ingredient (API) industry maintained its recovery momentum in 2025, with H1 revenue rising 1.5% year-on-year and profits increasing 5.6%. The sector's annual revenue reached 424.15 billion yuan in 2024. Import-export trade delivered strong performance, with total trade volume hitting $41.545 billion from January to September, up 4.7% YoY. Exports totaled $32.381 billion while imports stood at $9.165 billion, marking a gradual easing of the two-year "volume-for-price

Peptide APIs are substances formed by the dehydration and condensation of 10 to 100 amino acids, and are widely used in metabolic diseases, tumors, immune regulation and other fields due to their advantages of small side effects and strong specificity, and have entered a golden development period of both scale and quality since 2024.

Amino acid APIs cover pharmaceutical-grade, food-grade and other categories, among which pharmaceutical-grade products are the core raw materials for monoclonal antibodies, vaccines, injections, etc., and are also widely used in special medical food, health care products and other fields, and the industry growth is resilient.

On December 2, it was reported that the 24th World Pharmaceutical Raw Materials China Exhibition (CPHI & PMEC China 2026) will be held at the Shanghai New International Expo Center from June 16 to 18, 2026. The exhibition has a number of exhibition area upgrades, the original "Contract Customization Exhibition Area" has been renamed "Pharmaceutical Outsourcing Service Exhibition Area", covering one-stop outsourcing services from drug research and development to commercialization; The original "N

On June 26, some exhibitors analyzed the trend of the API industry based on the CPHI China 2025 exhibition. On the one hand, industry integration has accelerated, small and medium-sized pharmaceutical factories have been eliminated, resources have been concentrated in the leaders, and the profit growth rate of 32 leading companies in the API sector in 2024 will be significantly higher than the revenue growth rate; On the other hand, intelligent manufacturing has become the core of cost reduction